Biotech · Private company
Conatus Pharmaceuticals Inc.
Track this companyFree. Adds Conatus Pharmaceuticals Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- Emricasan (25 mg)Phase 2 · Decompensated CirrhosisClinicalTrials.gov · fetched Nov 12, 2026
- Emricasan (5 mg)Phase 2 · Decompensated CirrhosisClinicalTrials.gov · fetched Nov 12, 2026
- Emricasan (5 mg)Phase 2 · Non-alcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- Emricasan (50 mg)Phase 2 · Non-alcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- IDN-6556Phase 2 · Liver FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- UltrasoundLiver DiseasesClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or PlaceboTERMINATED · started Feb 27, 2018ClinicalTrials.gov NCT03479125 · fetched Nov 12, 2026
- Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17TERMINATED · started Jun 28, 2017ClinicalTrials.gov NCT03462576 · fetched Nov 12, 2026
- Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH CirrhosisPHASE2 · UNKNOWN · started Jun 28, 2017ClinicalTrials.gov NCT03205345 · fetched Nov 12, 2026
- Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) FibrosisPHASE2 · COMPLETED · started Jan 26, 2016ClinicalTrials.gov NCT02686762 · fetched Nov 12, 2026
- A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCVPHASE2 · COMPLETED · started May 1, 2014ClinicalTrials.gov NCT02138253 · fetched Nov 12, 2026